PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2016 Edition
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The report includes analysis of the numbers on 2015 drug approvals authorized by FDA’s CDER, CBER, Fast Track and Breakthrough drugs, and selected EMA approved drugs. The bottom line of this report is that a shrinking number of CMOs are getting the lion’s share of the contract manufactured new products. At least three harbingers were identified of a likely sustained increase in NME approvals in coming years: 1. Total approvals using a CMO grew, but the share of NDA that are outsourced was flat in 2015 2. The number of NDA approvals will continue to grow, which is good news for CMOs 3. But outsourcing by global bio/pharma companies may be on the decline PharmSource’s CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2016 Edition, concludes that these factors will provide both headwinds and tailwinds for the CMO industry. Additionally the report includes data that is valuable to CMOs offering dose manufacturing services. The 30-page report provides important insight that you won’t find in any other source. This report is required reading for: CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers. Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Scope
N/A
Reasons to Buy
N/A
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.